Large intestine

Treos Bio to Present New Clinical Data on Off-the-Shelf Peptide Immunotherapy for Colorectal Cancer at 2024 ASCO Annual Meeting

Retrieved on: 
Mercoledì, Maggio 8, 2024
Patient, Cancer, MSS, World Health Organization, Large intestine, Colorectal cancer, Progression-free survival, Immunotherapy, CRC, National Cancer Institute, Data science, Disease, Incidence, Neoplasm, Biomarker, Medical imaging

Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer-related deaths worldwide, according to the World Health Organization.

Key Points: 
  • Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer-related deaths worldwide, according to the World Health Organization.
  • In the United States, there are approximately 1.4 million people living with colorectal cancer, according to the National Cancer Institute.
  • Microsatellite Stable (MSS) CRC accounts for approximately 85 percent of all colorectal cancers and nearly all cases of metastatic CRC (mCRC).
  • PolyPEPI1018, Treos’ lead product candidate, is an off-the-shelf immunotherapy in clinical development for the treatment of metastatic colorectal cancer, co-developed with a candidate companion diagnostic.

Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Personalized Medicine in Middle East and North Africa (MEA) Region

Retrieved on: 
Lunedì, Maggio 6, 2024
Cancer, Merck Group, Large intestine, Death, MEA, RAS, CRC, SVP, Incidence, Patient, Medicine, Health, Colorectal cancer, EGFR, Merck, Pharmaceutical industry

Biocartis (Mechelen, Belgium) announced an expansion of its collaboration with Merck Serono Middle East and Merck Saudi Ltd., both affiliates of Merck KGaA (“Merck”).

Key Points: 
  • Biocartis (Mechelen, Belgium) announced an expansion of its collaboration with Merck Serono Middle East and Merck Saudi Ltd., both affiliates of Merck KGaA (“Merck”).
  • The collaboration aims to improve patient access to RAS biomarker testing in the Middle East and North Africa (MEA) region.
  • Colorectal cancer (CRC) is the third most common cancer worldwide, with an estimated incidence of more than 1.9 million new cases annually.
  • In our mission to enable universal access to personalized medicine for patients around the world, Biocartis is proud to provide Idylla™'s cutting-edge technology for mCRC testing across countries in the MEA region.

Exact Sciences Demonstrates Continued Scientific Advancement in Colorectal Cancer Screening with Multiple Data Presentations at DDW® 2024

Retrieved on: 
Martedì, Maggio 7, 2024
General Health, Health, Oncology, Simulation, Colorectal cancer, Gastrointestinal disease, Risk, Large intestine, Abstract, AGAF, Cohort, Exact sciences, Threshold, Disease, Trial, Exact Sciences (company), Patient, MPH, Mortality, DDW, Cancer, Incidence, Vaccine

This includes data on Cologuard®, the best-in-class non-invasive screening test for colorectal cancer in patients 45 and older at average risk, and the next-generation Cologuard test in development, Cologuard Plus™.

Key Points: 
  • This includes data on Cologuard®, the best-in-class non-invasive screening test for colorectal cancer in patients 45 and older at average risk, and the next-generation Cologuard test in development, Cologuard Plus™.
  • “At Exact Sciences, we know colorectal cancer screening must be able to find and also help prevent the disease to positively impact patient outcomes, which is how the Cologuard test was designed,” said Paul Limburg, MD, MPH, AGAF, chief medical officer for screening, Exact Sciences.
  • Up to 40% of the screening-eligible population in the U.S. currently needs to be screened for colorectal cancer and our data at DDW can inform strategies to meaningfully address this critical gap.”1
    The following abstracts from Exact Sciences have been accepted for presentation at the annual meeting:
    Session Title: Colorectal Cancer Screening and Surveillance: Cohort, Clinical Outcomes & Comparative Effectiveness Studies including Trials
    Session Title: Colorectal Cancer Screening and Surveillance: Cohort, Clinical Outcomes & Comparative Effectiveness Studies including Trials
    Session Title: Colorectal Cancer Screening and Surveillance: Cohort, Clinical Outcomes & Comparative Effectiveness Studies including Trials
    Presentation Title: Estimated Average-risk Colorectal Cancer Screening-eligible Population In The U.S.
  • Presentation Title: Impact Of Racial Disparities In The Quality Of Colonoscopy Screening On Colorectal Cancer Incidence And Mortality: A Simulation Modeling Analysis

FDA Approves ColoSense™ – Geneoscopy's Noninvasive Multi-target Stool RNA (mt-sRNA) Colorectal Cancer Screening Test

Retrieved on: 
Lunedì, Maggio 6, 2024
FDA, Other Health, Practice Management, Surgery, Managed Care, Oncology, Women, Medical Devices, Hospitals, Men, Biotechnology, Science, Consumer, Research, Health, Medical Supplies, Cancer, Food, Large intestine, Colorectal cancer, Methylation, Death, American Cancer Society, CRC, RNA, LH, Disease, Incidence, Patient, Colonoscopy, Biomarker, Ageing, Vaccine

Geneoscopy, Inc. , a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that the U.S. Food and Drug Administration (FDA) approved its noninvasive colorectal cancer screening test, ColoSense.

Key Points: 
  • Geneoscopy, Inc. , a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that the U.S. Food and Drug Administration (FDA) approved its noninvasive colorectal cancer screening test, ColoSense.
  • ColoSense is indicated as a screening test for adults, 45 years of age or older, who are at typical average risk for developing CRC.
  • Designated as a Breakthrough Device by the FDA, ColoSense is the first noninvasive colorectal cancer screening test to provide a dynamic view of disease activity by using RNA biomarkers.
  • Colorectal cancer is the second deadliest cancer in the United States.

Human Organoids Market Projected to Reach $2,124.91 million by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Venerdì, Aprile 12, 2024
Education, Alzheimer's disease, Molecular Devices, Merck Group, Investment, Danaher Corporation, Pancreatic cancer, Large intestine, Organoid, Colorectal cancer, Health, Corning Inc., Diabetes, Heart, Biomedical Research, Table, Research, Liver regeneration, Growth, Intelligence, B cell, Disease, Fatty liver disease, Thermo Fisher Scientific, Regenerative medicine, Toxicity, Biology, Drug development, Drug discovery, Government, Hepatitis, Pharmaceutical industry

Human organoids, the three-dimensional construct that simulate the intricate structure and function of human organs, are at the forefront of a revolution in medical research and patient care.

Key Points: 
  • Human organoids, the three-dimensional construct that simulate the intricate structure and function of human organs, are at the forefront of a revolution in medical research and patient care.
  • The key players in the Human Organoids Market include InSphero AG, Corning Incorporated, Molecular Devices, LLC by Danaher Corporation, Thermo Fisher Scientific Inc., Merck KGaA, and others.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Human Organoids Market.
  • "Dive into the Human Organoids Market Landscape: Explore 190 Pages of Insights, 382 Tables, and 24 Figures"

Human Organoids Market Projected to Reach $2,124.91 million by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Venerdì, Aprile 12, 2024
Education, Alzheimer's disease, Molecular Devices, Merck Group, Investment, Danaher Corporation, Pancreatic cancer, Large intestine, Organoid, Colorectal cancer, Health, Corning Inc., Diabetes, Heart, Biomedical Research, Table, Research, Liver regeneration, Growth, Intelligence, B cell, Disease, Fatty liver disease, Thermo Fisher Scientific, Regenerative medicine, Toxicity, Biology, Drug development, Drug discovery, Government, Hepatitis, Pharmaceutical industry

Human organoids, the three-dimensional construct that simulate the intricate structure and function of human organs, are at the forefront of a revolution in medical research and patient care.

Key Points: 
  • Human organoids, the three-dimensional construct that simulate the intricate structure and function of human organs, are at the forefront of a revolution in medical research and patient care.
  • The key players in the Human Organoids Market include InSphero AG, Corning Incorporated, Molecular Devices, LLC by Danaher Corporation, Thermo Fisher Scientific Inc., Merck KGaA, and others.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Human Organoids Market.
  • "Dive into the Human Organoids Market Landscape: Explore 190 Pages of Insights, 382 Tables, and 24 Figures"

EQS-News: Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options

Retrieved on: 
Mercoledì, Aprile 10, 2024
Colorectal cancer, Large intestine, Marker beacon, Certification, Risk assessment, Pharmacist, Physician, BDH

BERKELEY, US – MAINZ, Germany – March 18th 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, in collaboration with Ganzimmun, will host an educational webinar on Early Detection of Colorectal Cancer: New Laboratory Diagnostic Options which is taking place on March 20, 2024.

Key Points: 
  • BERKELEY, US – MAINZ, Germany – March 18th 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, in collaboration with Ganzimmun, will host an educational webinar on Early Detection of Colorectal Cancer: New Laboratory Diagnostic Options which is taking place on March 20, 2024.
  • Designed for pharmacists, physicians, and healthcare professionals, this online training session aims to shed light on innovative laboratory diagnostic approaches for colorectal cancer screening.
  • Set against the backdrop of March's Colorectal Cancer Awareness Month, the webinar will delve into the significance of genetic markers and the advancements in screening techniques that offer a more accurate risk assessment and early detection.
  • Title: Darmkrebs-Früherkennung: Neue labordiagnostische Optionen (Early Detection of Colorectal Cancer: New Laboratory Diagnostic Options)

Early Detection of Colorectal Cancer Saves Lives - Colorectal Cancer Resource & Action Network (CCRAN) and BUMRUN Join Forces to Promote Colorectal Cancer Awareness in Canada

Retrieved on: 
Martedì, Aprile 9, 2024
Large intestine, Patient, Colorectal cancer, Organic, Cancer, Disease

TORONTO, April 9, 2024 /CNW/ - Colorectal cancer is the second leading cause of cancer-related death in Canada.

Key Points: 
  • TORONTO, April 9, 2024 /CNW/ - Colorectal cancer is the second leading cause of cancer-related death in Canada.
  • Despite being the most preventable cancer through screening, 50% of colorectal cancer cases are diagnosed at advanced stages .
  • Increasing awareness of early symptoms and screening programs is therefore crucial to reducing the burden of this disease in Canada.
  • You can make a difference in the lives of colorectal cancer patients in Canada by participating in and/or fundraising for CCRAN at BUMRUN's annual 5k walk/run events.

Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options

Retrieved on: 
Lunedì, Marzo 18, 2024
Colorectal cancer, Large intestine, Marker beacon, Certification, Risk assessment, Pharmacist, Physician, BDH

BERKELEY, Calif. and MAINZ, Germany, March 18, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, in collaboration with Ganzimmun, will host an educational webinar on Early Detection of Colorectal Cancer: New Laboratory Diagnostic Options which is taking place on March 20, 2024.

Key Points: 
  • BERKELEY, Calif. and MAINZ, Germany, March 18, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, in collaboration with Ganzimmun, will host an educational webinar on Early Detection of Colorectal Cancer: New Laboratory Diagnostic Options which is taking place on March 20, 2024.
  • Designed for pharmacists, physicians, and healthcare professionals, this online training session aims to shed light on innovative laboratory diagnostic approaches for colorectal cancer screening.
  • Set against the backdrop of March's Colorectal Cancer Awareness Month, the webinar will delve into the significance of genetic markers and the advancements in screening techniques that offer a more accurate risk assessment and early detection.
  • Title: Darmkrebs-Früherkennung: Neue labordiagnostische Optionen (Early Detection of Colorectal Cancer: New Laboratory Diagnostic Options)

Fight Colorectal Cancer Unites Over 200 Advocates in Washington, D.C. for the 18th Annual Call-on Congress Event

Retrieved on: 
Martedì, Marzo 12, 2024
JAMA, Colorectal cancer, Congress, Disease, Caregiver, Incidence, Ageing, Exact sciences, Research, Woman, Statistics, Survivor, CDC, CRC, Large intestine, Dairy

WASHINGTON, D.C., March 12, 2024 (GLOBE NEWSWIRE) -- In a powerful display of unity, Fight Colorectal Cancer (Fight CRC) is hosting the 18th Annual Call-on Congress event, bringing together over 200 colorectal cancer survivors, caregivers, and loved ones.

Key Points: 
  • WASHINGTON, D.C., March 12, 2024 (GLOBE NEWSWIRE) -- In a powerful display of unity, Fight Colorectal Cancer (Fight CRC) is hosting the 18th Annual Call-on Congress event, bringing together over 200 colorectal cancer survivors, caregivers, and loved ones.
  • This landmark advocacy initiative aims to elevate personal stories and press for increased funding and support to combat colorectal cancer (CRC) .
  • Colorectal cancer, encompassing colon and rectal cancers, stands as the second-leading cause of cancer deaths for both men and women combined in the United States.
  • Encouraging Members of Congress to Champion Colorectal Cancer : Advocates will call on their representatives to become champions for colorectal cancer, actively working to transform the statistics surrounding the disease by joining the Colorectal Cancer Caucus.